Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Targeted metabolomics provides an approach to quantify metabolites involved in specific molecular pathways. We applied an electrochemistry-based, targeted metabolomics platform to define changes in tryptophan, tyrosine, purine and related pathways in the depressed and remitted phases of major depressive disorder (MDD). Biochemical profiles in the cerebrospinal fluid of unmedicated depressed (n = 14; dMDD) or remitted MDD subjects (n = 14; rMDD) were compared against those in healthy controls (n = 18; HC). The rMDD group showed differences in tryptophan and tyrosine metabolism relative to the other groups. The rMDD group also had higher methionine levels and larger methionine-to-glutathione ratios than the other groups, implicating methylation and oxidative stress pathways. The dMDD sample showed nonsignificant differences in the same direction in several of the metabolic branches assessed. The reductions in metabolites associated with tryptophan and tyrosine pathways in rMDD may relate to the vulnerability this population shows for developing depressive symptoms under tryptophan or catecholamine depletion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The same group of patients also showed changes in the methionine-to-glutathione ratio, indicating alterations in OS and methylation.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An analysis of the tryptophan, tyrosine, purine pathways, and associated pathways revealed that in patients in remission, methionine levels were higher, while tryptophan and tyrosine levels were lower.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The levels of these same metabolites were altered in MDD patients who were not taking medication, although not to a significant degree. 467”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametrics: Statistical Methods Based on Ranks
Mergenthaler, M. J., & Lehmann, E. L. (1979) · Technometrics · doi:10.2307/1268531 · Cited by 3,329
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307
Limbic-cortical dysregulation: a proposed model of depression
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.471 · Cited by 1,585
Discovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Self-citationMetabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670
Self-citationGawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594
GABAergic dysfunction in mood disorders
Brambilla, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001362 · Cited by 553
The implications of human metabolic network topology for disease comorbidity
Lee, D.-S., Park, J., Kay, K. A., Christakis, N. A., Oltvai, Z. N., & Barabási, A.-L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802208105 · Cited by 495
Interferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Stahl, S. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0103 · Cited by 489
Serotonin and dopamine: unifying affective, activational, and decision functions.
Cools, R., Nakamura, K., & Daw, N. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.121 · Cited by 464
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
Abdolmaleky, H. M., Cheng, K.-H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., Smith, C. L., Shafa, R., Aeali, B., Carnevale, J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl253 · Cited by 462
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Melfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1128 · Cited by 409
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Bogdanov, M., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R., Bressman, S. S., & Beal, M. F. (2008) · Brain · doi:10.1093/brain/awm304 · Cited by 401
Self-citationAntioxidant enzyme activities and oxidative stress in affective disorders
Erkan Ozcan, M., Gulec, M., Ozerol, E., Polat, R., & Akyol, O. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00006 · Cited by 368
Stockmeier, C. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00050-5 · Cited by 358
Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293
Self-citationCSF monoamine metabolites in melancholia
Åsberg, M., Bertilsson, L., Mårtensson, B., Scalia‐Tomba, G. ‐., Thorén, P., & Träskman‐Bendz, L. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb02488.x · Cited by 289
Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263
Metabonomics in pharmaceutical R & D
Lindon, J. C., Holmes, E., & Nicholson, J. K. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05673.x · Cited by 262
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262
Inoue, T., Tsuchiya, K., & Koyama, T. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90243-7 · Cited by 262
Role of norepinephrine in depression.
Delgado, P. L., & Moreno, F. A. (2000) · PubMed · Cited by 251
Hasler, G., Fromm, S., Carlson, P. J., Luckenbaugh, D. A., Waldeck, T., Geraci, M., Roiser, J. P., Neumeister, A., Meyers, N., Charney, D. S., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.521 · Cited by 209
Self-citationResidual symptoms at remission from depression: Impact on long-term outcome
Kennedy, N., & Paykel, E. S. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00054-5 · Cited by 199
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.12.1539 · Cited by 191
Fatty acids and oxidative stress in psychiatric disorders
Tsaluchidu, S., Cocchi, M., Tonello, L., & Puri, B. K. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-s1-s5 · Cited by 179
Lan, M. J., McLoughlin, G. A., Griffin, J. L., Tsang, T. M., Huang, J. T. J., Yuan, P., Manji, H., Holmes, E., & Bahn, S. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002130 · Cited by 178
Self-citationMetabolomic analysis and signatures in motor neuron disease
Rozen, S., Cudkowicz, M., Bogdanov, M. B., Matson, W. R., Kristal, B. S., Beecher, C., Harrison, S. J., Vouros, P., Flarakos, J., Vigneau-Callahan, K. E., et al. (2005) · Metabolomics · doi:10.1007/s11306-005-4810-1 · Cited by 164
Self-citationRole of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Cui, J., Shao, L., Young, L. T., & Wang, J.-F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.010 · Cited by 160
Ji, Y., Hebbring, S., Zhu, H., Jenkins, G. D., Biernacka, J., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.250 · Cited by 160
Self-citationMetabolomic Profiling in LRRK2-Related Parkinson's Disease
Johansen, K. K., Wang, L., Aasly, J. O., White, L. R., Matson, W. R., Henchcliffe, C., Beal, M. F., & Bogdanov, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007551 · Cited by 155
Self-citation5-HT receptor binding in post-mortem brain from patients with affective disorder
McKeith, I. G., Marshall, E. F., Ferrier, I. N., Armstrong, M. M., Kennedy, W. N., Perry, R. H., Perry, E. K., & Eccleston, D. (1987) · Journal of Affective Disorders · doi:10.1016/0165-0327(87)90075-9 · Cited by 142
Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.5.591 · Cited by 138
A preliminary metabolomic analysis of older adults with and without depression
Paige, L. A., Mitchell, M. W., Krishnan, K. R. R., Kaddurah‐Daouk, R., & Steffens, D. C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1690 · Cited by 136
Self-citationCommon pathways of depression and pain.
Delgado, P. L. (2004) · PubMed · Cited by 135
Sanacora, G., & Saricicek, A. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363294 · Cited by 131
Wikoff, W. R., Pendyala, G., Siuzdak, G., & Fox, H. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34138 · Cited by 131
Dempster, E. L., Mill, J., Craig, I. W., & Collier, D. A. (2006) · BMC Medical Genetics · doi:10.1186/1471-2350-7-10 · Cited by 129
Bhagwagar, Z., & Cowen, P. J. (2008) · Psychological Medicine · doi:10.1017/s0033291707001250 · Cited by 124
Yao, J. K., Dougherty, G. G., Reddy, R. D., Keshavan, M. S., Montrose, D. M., Matson, W. R., Rozen, S., Krishnan, R. R., McEvoy, J., & Kaddurah-Daouk, R. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.33 · Cited by 118 · cited 2×
“Naı̈ve to antidepressant treatment: n (%) 18 (100) 4 (29) 2 (14) Time unmedicated (mos): mean 6 SD (range n.”
Self-citationKling, M. A., Alesci, S., Csako, G., Costello, R., Luckenbaugh, D. A., Bonne, O., Duncko, R., Drevets, W. C., Manji, H. K., Charney, D. S., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.033 · Cited by 111
Self-citationNeumeister, A., Young, T. A., & Stastny, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1950-3 · Cited by 106
Self-citationEnhanced negative feedback responses in remitted depression
Santesso, D. L., Steele, K. T., Bogdan, R., Holmes, A. J., Deveney, Meites, T. M., & Pizzagalli, D. A. (2008) · NeuroReport · doi:10.1097/wnr.0b013e3283036e73 · Cited by 106
Depression vulnerability and 5-hydroxytryptophan prophylaxis
van Praag, H. M., & de Haan, S. (1980) · Psychiatry Research · doi:10.1016/0165-1781(80)90049-9 · Cited by 101
Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders
Vestergaard, P., Sørensen, T., Hoppe, E., Rafaelsen, O. J., Yates, C. M., & Nicolaou, N. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb06924.x · Cited by 100
An optimised sample preparation method for NMR-based faecal metabonomic analysis
Wu, J., An, Y., Yao, J., Wang, Y., & Tang, H. (2010) · The Analyst · doi:10.1039/b927543f · Cited by 98
Self-citationMcGowan, P. O., & Kato, T. (2007) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-007-0002-0 · Cited by 95
CSF monoamine metabolites of depressed patients during illness and after recovery
Träskman‐Bendz, L., Åsberg, M., Bertilsson, L., & Thorén, P. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb02503.x · Cited by 86 · cited 1×
“23 Race (% Caucasian) 78 89 36 Current cigarette smoker: n (% of cases) 4 (29) 6 (43) Past suicide attempts: n (% of cases) 0 (0) 2 (14) 3 (21) Age at illness-onset (yrs): mean 6 SD n.”
Markers of dopamine metabolism in Parkinson's disease
LeWitt, P. A., Galloway, M. P., Matson, W. R., Milbury, P. E., McDermott, M., Srivastava, D. K., Oakes, D., & the Parkinson Study Group (1992) · Neurology · doi:10.1212/wnl.42.11.2111 · Cited by 84
Self-citationIncreased oxidative stress in submitochondrial particles after chronic amphetamine exposure
Frey, B. N., Valvassori, S. S., Gomes, K. M., Martins, M. R., Dal‐Pizzol, F., Kapczinski, F. P., & Quevedo, J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.04.076 · Cited by 82
Postmortem Neurochemical Studies in Depression
Ferrier, I. N., McKeith, I. G., Cross, A. J., Perry, E. K., Candy, J. M., & Perry, R. H. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb27893.x · Cited by 78
Epigenetic Alterations of the Dopaminergic System in Major Psychiatric Disorders
Abdolmaleky, H. M., Smith, C. L., Zhou, J.-R., & Thiagalingam, S. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-205-2_9 · Cited by 74
Sheline, Y. I., Bardgett, M. E., & Csernansky, J. G. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199702000-00003 · Cited by 74
Vigneau-Callahan, K. E., Shestopalov, A. I., Milbury, P. E., Matson, W. R., & Kristal, B. S. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.3.924s · Cited by 73
Self-citationClaxton, A. J., Li, Z., & McKendrick, J. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.2.163 · Cited by 68
Metabolomic Differences in Heart Failure Patients With and Without Major Depression
Steffens, D. C., Jiang, W., Krishnan, K. R. R., Karoly, E. D., Mitchell, M. W., O'Connor, C. M., & Kaddurah-Daouk, R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709358592 · Cited by 68
Self-citationNew Evidence of Serotonin-Deficient Depressions
van Praag, H. M. (2008) · Neuropsychobiology · doi:10.1159/000117590 · Cited by 65
Moreno, F. A., Parkinson, D., Palmer, C., Castro, W. L., Misiaszek, J., El Khoury, A., Mathé, A. A., Wright, R., & Delgado, P. L. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.10.003 · Cited by 61
Hasler, G., Luckenbaugh, D. A., Snow, J., Meyers, N., Waldeck, T., Geraci, M., Roiser, J., Knutson, B., Charney, D. S., & Drevets, W. C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.029 · Cited by 61
Self-citationKristal, B. S., Vigneau-Callahan, K. E., & Matson, W. R. (1998) · Analytical Biochemistry · doi:10.1006/abio.1998.2831 · Cited by 58
Self-citationKristal, B. S., Shurubor, Y. I., Kaddurah-Daouk, R., & Matson, W. R. (2007) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-244-1_10 · Cited by 55
Self-citationMårtensson, B., Wägner, A., Beck, O., Brodin, K., Montero, D., & Åsberg, M. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb07377.x · Cited by 49
Metabolomics in the Study of Aging and Caloric Restriction
Kristal, B. S., Shurubor, Y. I., Kaddurah-Daouk, R. F., & Matson, W. R. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-361-5_25 · Cited by 39
Self-citationFenfluramine challenge test as a predictor of outcome in major depression.
Malone, K. M., Thase, M. E., Mieczkowski, T. A., Myers, J. E., Stull, S. D., Cooper, T. B., & Mann, J. J. (1993) · PubMed · Cited by 37
CENTRAL SEROTONIN DEFICIENCY—A FACTOR WHICH INCREASES DEPRESSION VULNERABILITY?
van Praag, H. M., & de Haan, S. (1980) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.1980.61.s280.89 · Cited by 35
Roy, A. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.4.557-b · Cited by 33
Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans
Carpenter, L. L., Anderson, G. M., Siniscalchi, J. M., Chappell, P. B., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300025 · Cited by 32
Ågren, H., Niklasson, F., & Hällgren, R. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90042-2 · Cited by 30
Niklasson, F., Ågren, H., & Hällgren, R. (1983) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.46.3.255 · Cited by 30
Computations using analysis of covariance
Barrett, T. J. (2011) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.165 · Cited by 28
Affective disorders and S-adenosylmethionine: a new hypothesis
Cantoni, G. L., Mudd, S. H., & Andreoli, V. M. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90038-6 · Cited by 24
Shi, W., & Palmer, C. P. (2002) · Electrophoresis · Cited by 23
Lundmark, J., Wålinder, J., Alling, C., Manniche, P. M., & Dalgaard, L. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90308-5 · Cited by 22
Nordin, C. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06411.x · Cited by 16 · cited 2×
“Naı̈ve to antidepressant treatment: n (%) 18 (100) 4 (29) 2 (14) Time unmedicated (mos): mean 6 SD (range n.”
Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment
Bäckman, J., Alling, C., Alsén, M., Regnéll, G., & Träskman‐Bendz, L. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00089-4 · Cited by 13 · cited 1×
“23 Race (% Caucasian) 78 89 36 Current cigarette smoker: n (% of cases) 4 (29) 6 (43) Past suicide attempts: n (% of cases) 0 (0) 2 (14) 3 (21) Age at illness-onset (yrs): mean 6 SD n.”
Immunoaffinity screening with capillary electrochromatography
Mayer, M., Muscate, A., Vogel, H., Ehrat, M., & Bruin, G. J. M. (2002) · Electrophoresis · doi:10.1002/1522-2683(200205)23:9<1320::aid-elps1320>3.0.co;2-9 · Cited by 7
Research works printed but not linked: 3
- Delgado, P. L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6, 7–11 (2000).
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Washington, DC American Psychiatric Association; 1994.
- First, M. B., Spitzer, R. L., Gibbon, M. & William, J. B. W. Structured Clinical Interview fpr DSM-IV-TR Axis 1 disorders, Research Version, Patient Edition (SCID-I/P) New York, NY: New York State Psychiatric Institute, Biometric research; 2002. 73 Maxwell, M. (Bethesda, MD, 1992).
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Effects of pre-analytical processes on blood samples used in metabolomics studies
Yin, P., Lehmann, R., & Xu, G. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8565-x · Cited by 278
Savitz, J., Drevets, W. C., Wurfel, B. E., Ford, B. N., Bellgowan, P. S. F., Victor, T. A., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.02.007 · Cited by 209
“Further, a reduction in the 5-hydroxyindoleacetic acid to kynurenine ratio was found in the cerebrospinal fluid of unmedicated rMDD patients compared with both dMDD patients and HCs, suggesting greater shunting of TRP away from serotonin synthesis towards the kynurenine metabolic pathway (Kaddurah-Daouk et al., 2012).”
ResultSelf-citationPharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology
Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.217 · Cited by 188
Self-citationThe Glutathione System: A New Drug Target in Neuroimmune Disorders
Morris, G., Anderson, G., Dean, O., Berk, M., Galecki, P., Martin-Subero, M., & Maes, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8705-x · Cited by 187
“3 months without medication to be included [250].”
BackgroundResult
Metadata
- Authors
- Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., Guitart, X., Carlson, P. J., Neumeister, A., Zarate, C., Krishnan, R. R., Manji, H. K., & Drevets, W.
- Affiliations
- Duke University (US)
- National Institutes of Health (US)
- Edith Nourse Rogers Memorial Veterans Hospital (US)
- North Carolina State University (US)
- VA Pittsburgh Healthcare System (US)
- National University of Singapore (SG)
- Corresponding author
- Kaddurah-Daouk, Rima
- ORCID
- Venue
- Scientific Reports
- Published
- 2012-09-19
- Volume
- 2
- Issue
- 1
- Pages
- 667-667
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3446657
- OpenAlex
- W1971315623
- Cited by
- 76
- References
- 77
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 7 · 2014: 6 · 2013: 5 · 2012: 1
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Institute of Mental Health
- National Institute of General Medical Sciences (R24GM078233)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- major depressive disorder, remission, tryptophan metabolism, tyrosine metabolism, purine metabolism, methionine, methylation, oxidative stress, catecholamine depletion, depression vulnerability
- MeSH terms
- Adult, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Remission, Spontaneous, Severity of Illness Index, Biogenic Monoamines, Multivariate Analysis, Case-Control Studies, Biosynthetic Pathways, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.